Dermaliq Therapeutics, Inc.
🇺🇸United States
Safety and Efficacy Study of Topical DLQ01 in the Treatment of Androgenetic Alopecia (AGA) in Men
Phase 1
Completed
- Conditions
- Androgenetic Alopecia
- Interventions
- Drug: prostaglandin F2a analogue in vehicle solution high doseDrug: prostaglandin F2a analogue in vehicle solution low doseDrug: active ingredient-free vehicle solution to DLQ01
- First Posted Date
- 2022-12-05
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- Dermaliq Therapeutics, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT05636904
- Locations
- 🇦🇺
Dr Rodney Sinclair Pty Ltd,, Pascoe Vale South, Victoria, Australia
© Copyright 2025. All Rights Reserved by MedPath